Analysts forecast that Check Cap Ltd (NASDAQ:CHEK) will announce earnings per share (EPS) of ($0.82) for the current quarter, according to Zacks. Zero analysts have issued estimates for Check Cap’s earnings. Check Cap reported earnings of ($1.92) per share during the same quarter last year, which would indicate a positive year over year growth rate of 57.3%. The business is expected to announce its next quarterly earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Check Cap will report full year earnings of ($4.99) per share for the current financial year, with EPS estimates ranging from ($7.20) to ($2.77). For the next financial year, analysts expect that the company will report earnings of ($1.36) per share. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Check Cap.
Check Cap (NASDAQ:CHEK) last released its earnings results on Thursday, May 17th. The medical research company reported ($1.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.68) by $0.41.
A hedge fund recently bought a new stake in Check Cap stock. Armistice Capital LLC bought a new position in shares of Check Cap Ltd (NASDAQ:CHEK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 748,000 shares of the medical research company’s stock, valued at approximately $651,000. Armistice Capital LLC owned approximately 3.88% of Check Cap at the end of the most recent quarter.
NASDAQ CHEK opened at $4.16 on Friday. Check Cap has a 12 month low of $3.12 and a 12 month high of $24.36.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.